INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Regenxbio and its officers or directors following a significant stock price drop due to FDA clinical holds on its gene therapies [1][2]. Group 1: Company Overview - Regenxbio Inc. is a biotechnology company focused on gene therapy, specifically for conditions such as MPS I (Hurler syndrome) and MPS II (Hunter syndrome) [2]. - The company’s stock price fell by $2.40, or 17.9%, closing at $11.01 per share on January 28, 2026, after the announcement of the FDA's clinical holds [2]. Group 2: Regulatory Developments - The FDA placed a clinical hold on Regenxbio's investigational gene therapy RGX-111 due to a case of neoplasm in a participant from its Phase I/II study [2]. - A similar clinical hold was also placed on RGX-121, citing shared risks between the two studies [2]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [3].